Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET
Objective: We compared 2 novel MRI techniques: neuromelanin-sensitive MRI (NM-MRI) and susceptibility weighted imaging (SWI) with [11C]PE2I PET in order to establish their validity as biomarkers…MRI based Volumetric analysis of the sub-thalamic and red nuclei in Advanced Parkinson’s disease- an institutional study
Objective: •To evaluate volume of Sub thalamic and Red nuclei on 3T MRI and its 3D reconstruction and its possible correlation with the disease progression in…Clinico-pathological Findings In Autopsy Cases With Non-Specific Glial Tauopathy
Objective: Determine Clinico-pathological correlates of aging-related tau astrogliopathy (ARTAG). Background: Aging-related tau astrogliopathy (ARTAG) appears to be a morphological spectrum of astroglial pathology mostly seen in…Mu opioid receptor agonism, not antagonism, for the treatment of L-DOPA-induced dyskinesia in Parkinson’s disease
Objective: To reappraise the role of the µ opioid receptor as a therapeutic target for L-DOPA-induced dyskinesia. Background: Parkinson’s disease (PD) is commonly treated with…Treatment of subcutaneous nodules after subcutaneous infusion of apomorphine
Objective: To evaluate the efficacy of 4 treatment modalities on apomorphine-induced subcutaneous nodules as compared to no treatment. Background: Subcutaneous nodules are the most common adverse events…Association of genetic polymophisms with pharmacokinetics of levodopa in South indian PD patients
Objective: To evaluate the role of COMT gene variations on the pharmacokinetics (PK) of L-dopa in PD patients. Background: Genetic variations in enzymes (MAO-B, COMT),…Ferroptosis, a recently identified cell death, as a therapeutic target for Parkinson’s disease.
Objective: We aim to determine in a cell model neuroprotective effects of targeting lipoxygenases (LOXs), central players in Ferroptosis, a novel regulated iron-dependent cell death…The Frequency, Causes and Risk Factors of Discontinuation of Dopamine Agonists in Parkinson’s Disease Patients
Objective: To determine the incidence, causes and risk factors of dopamine agonists (pramipexole and ropinirole) discontinuation in Parkinson’s disease patients. Background: Ropinirole and pramipexole are…Sudden alopecia secondary to levodopa treatment
Objective: Report a rarely documented side effect of dopaminergic therapy and review the literature on this aspect, highlighting the underlying mechanisms hypothetically involved. Background: Levodopa…Development of Mucoadhesive Sustained Release Floating Tablets of Silymarin using Natural Polymer for Improved Anti-Parkinson Efficacy
Objective: The objective of the present investigation was to develop Mucoadhesive sustained release floating tablets of Silymarin using natural polymers (Coccinia grandis and Rumex vasicarious)…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.